This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Northwest Bio Fails to Refute MD Anderson Rebuke

06/20/14 - 09:41 AM EDT

Conspicuously absent from Northwest Biotherapeutics' press release Friday was any mention of the MD Anderson Cancer Center.

READ FULL POST

Bluebird Bio Higher on Strong Gene Therapy Study Results

06/16/14 - 07:28 AM EDT

Two patients with a serious, inherited blood disorder have been able to stop blood transfusions following a single treatment with an experimental gene therapy developed by Bluebird Bio, according to new but preliminary data presented Saturday.

READ FULL POST

Analyst Goes to Sweden, Returns Home Predicting Vertex CF Drug Failure

06/16/14 - 07:01 AM EDT

Bernstein analyst Geoff Porges hung out with doctors and cystic fibrosis experts at the just-concluded European Cystic Fibrosis Society conference in Sweden and returned home even more bearish on Vertex Pharmaceuticals. In a research note Monday, Porges lays out reasons why the super-important combination studies of Kalydeco and VX-809 -- TRAFFIC and TRANPORT -- are more likely to fail.

READ FULL POST

Galena Promoting Experimental Breast Cancer Drug With Faux News Articles Again

06/13/14 - 10:11 AM EDT

Galena is paying a marketing firm to create promotions for its experimental breast cancer vaccine Neuvax. These Neuvax ads are dressed up to like legitimate news articles, except for the small disclaimer labeling them as "sponsored content paid for by a third party..."

READ FULL POST

FDA Delays Decision on Orexigen Obesity Pill by 3 Months

06/11/14 - 06:48 AM EDT

FDA needs more time to reach agreement on the post-marketing obligation related to the previously agreed upon evaluation of heart-safety related outcomes for Contrave, Orexigen said

READ FULL POST

Inovio CEO Preps Retail Investors for Drug Study Failure

06/10/14 - 12:23 PM EDT

Inovio Pharmaceuticals CEO Joseph Kim is walking back expectations for the phase II study of its DNA vaccine VGX-3100 in women with high-grade cervical intraepithelial neoplasia (CIN 2/3), also known as cervical pre-cancerous lesions. Results from the VGX-3100 study should be announced any day, but I suspect Inovio already has data in hand. Why else would Kim be laying the foundation for a massive spin job, if not to cushion the vaccine's failure?

READ FULL POST

Achillion Hep C Drug Update is Well Timed

06/10/14 - 08:36 AM EDT

Talk about uncanny timing, one day after Achillion Pharmaceuticals rips higher on takeover speculation, the company announces the lifting of an FDA clinical hold on its lead hepatitis C drug candidate and the start of a new study with a second hepatitis C compound.

READ FULL POST

Dendreon CEO Exits Ahead of Big Debt Payment

06/09/14 - 04:38 PM EDT

The desperate Dendreon debacle just descended into despondency with the abrupt departure of Chairman and CEO John Johnson, citing "personal reasons."

READ FULL POST

Achillion Pharma Might be Next Hep C Takeout Target

06/09/14 - 09:22 AM EDT

Johnson & Johnson and Abbvie were both reportedly interesting in buying Idenix but lost out to Merck, reports CNBC. Achillion shares are up almost 30% to $TK Monday as investors bet the losers in the Idenix sweepstakes may move on to the next target.

READ FULL POST

Merck Buys Idenix for $3.9B in Yet Another Blockbuster Hep C Deal

06/09/14 - 08:27 AM EDT

With Gilead Sciences already marketing the hepatitis C pill Sovaldi and competition from Abbvie-Enanta Pharma and Bristol-Myers Squibb close behind, a lot of investors believed the hepatitis C drug race had transitioned to marketing and away from M&A. But Merck chief scientitist Roger Perlmutter is no dummy, so his decision to spend almost $4 billion on Idenix says the hepatitis C treatment market may have a much longer tail than many believed.

READ FULL POST

Adam Feuerstein is a senior columnist at TheStreet in charge of covering biotechnology and pharmaceutical stocks.

Feuerstein has been a financial journalist for more than 20 years. He joined TheStreet in 2001, leaving in 2005 for a two-year stint as a biotech analyst for a New York-based investment management firm. Feuerstein rejoined TheStreet in 2007. Prior to his work at TheStreet, Feuerstein wrote about Internet startups and business software for Upside.com. Covering the dot-com boom and bust of the 1990s and early 2000s made Feuerstein very cynical, a trait he applies to great effect by highlighting the often-overlooked risks of biotech stock investing. In what can only be considered a high compliment, a particularly promotional sell-side analyst once warned his clients that Feuerstein "attacks viciously".

Expand Bio +

Feuerstein lives near Boston with his wife, two kids and a yellow lab-golden retriever named Max. When Feuerstein is not writing article and blog posts for TheStreet, he's tweeting. In fact, when Feuerstein is working, he's tweeting. All the time. He also runs, bikes, watches a lot of English soccer matches (Go Spurs!) and loves to cook.

Close Bio -

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Adam's Tweets

Brokerage Partners

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs